Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIRX002
- Development stage
- Unknown
- Lead developer
- PURMX Therapeutics
- Modality
- miRNA Inhibitors → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, miRNA Mimics → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathoracic, Intravenous
01
Overview
MIRX002 is a microRNA-based anticancer therapeutic developed by PURMX Therapeutics, a Hiroshima University spin-off. The drug is a synthetic mimic of miR-3140-3p, a naturally occurring microRNA that targets cancer stem cells to inhibit tumor growth, progression, and recurrence. To overcome the challenges of nucleic acid stability and delivery, MIRX002 utilizes the surfactant peptide A6K as a delivery carrier, which protects the miRNA from enzymatic degradation until it reaches the target cells. It is currently being evaluated in Phase 1/2 clinical trials for malignant pleural mesothelioma (MPM) and head and neck squamous cell carcinoma (HNSCC). The U.S. FDA has granted Orphan Drug Designation to miR-3140-3p for the treatment of mesothelioma.
- Other names
- miR-3140-3pmiR3140-3pmiR 3140-3pmiR-3140miR3140miR 3140
02
Targets
MYC (MYC proto-oncogene protein)MYCN (N-myc proto-oncogene protein)MAP3K3
Beyond the preview
Go deeper on MIRX002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIRX002.